跳至主要内容
临床试验/NCT04334694
NCT04334694Unknown不适用

Pomeranian atRial flOw reguLatOr iN conGestive hEart failuRe (PROLONGER) Trial

Szpitale Pomorskie Sp. z o. o.2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2020年1月7日最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
试验地点
2
主要终点
Clinical improvement

研究概览

简要总结

The aim of the study is to assess invasive and non-invasive parameters that may predict clinical improvement in patients with congestive heart failure after implantation of Occlutech® Atrial flow regulator (AFR) device.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Symptomatic heart failure (HF) in NYHA class III or IV ambulatory
  • Optimal medical therapy of HF according to European Society of Cardiology (ESC) guidelines for last 6 months
  • Hospitalization because of HF decompensation in last 12 months
  • Absence of significant valvular disease requiring cardiac surgery
  • Life expectancy ≥ 1 year
  • Written informed consent obtained from the patient
  • Left ventricle ejection fraction (LVEF) ≥ 15%
  • Elevated left heart filling pressures:
  • Pulmonary artery wedge pressure (PAWP) at rest > 15 mmHg or
  • PAWP > 25 mmHg during hand grip test

排除标准

  • Participation in another clinical trial in last 30 days
  • Acute infection or sepsis
  • Severe coagulation disorder
  • Allergy to nickel or titanium
  • Severe peripheral artery disease disabling 6 minutes walk test
  • Allergy to antiplatelet drugs, oral anticoagulants or heparin
  • Contraindication to trans-oesophageal echocardiography (TEE)
  • Pregnancy
  • Atrial septal defect (ASD) or presence of atrial septal occluder
  • Severe patent foramen ovale (PFO) with significant left to right shunt in rest
  • Intracardiac thrombus
  • Acute coronary syndrome or Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) in last 6 months
  • Severe pulmonary hypertension:
  • Right atrial pressure ≥ PAWP (measured in right heart catheterization)
  • Right atrial pressure > 20 mmHg (measured in right heart catheterization)
  • Planned heart transplantation
  • Transient ischemic attack or stroke within last 6 months
  • Cardiac resynchronisation therapy (CRT) within last 6 months

结局指标

主要结局

Clinical improvement

时间窗: 12 months

Increase in 6 minutes walk test distance

次要结局

  • Clinical improvement II(12 months)
  • Device related adverse event(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Atrial Flow Regulator in Heart Failure | 临床试验